Obesity

ClinicalJuly 20, 2026

Amgen's MARITIME-2-EXTENSION Trial Evaluates Maridebart Cafraglutide for Obesity and Type 2 Diabetes

Amgen is conducting an extension trial to assess the long-term efficacy, safety, and tolerability of maridebart cafraglutide in patients with obesity and type 2 diabetes.

Sponsor company

Mechanism of action

Recent signals(6)

Amgen's MARITIME-2-EXTENSION Trial Evaluates Maridebart Cafraglutide for Obesity and Type 2 Diabetes

Study on Endoscopic Gastric Mucosal Ablation for Class III Obesity Initiated

Roche to Present Phase II Data on Enicepatide and Petrelintide at ADA 2026

Roche to Present Phase II Data on Enicepatide and Petrelintide at ADA 2026

Foundayo shows significant weight reduction in older adults with obesity in new analysis

Lilly's retatrutide shows significant weight loss in Phase 3 obesity trial

Upcoming milestones

Related catalysts

Indications

Therapeutic areas

Get signals before the market moves